Beam Therapeutics Inc.

XNASHealth care

Last traded price · USD

$27.61

−0.65%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:04 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $27.79
Volume: 667
Day's high: —
Day's low: —

In brief

Beam Therapeutics Inc. is a health care company listed on Nasdaq, valued at about $2.85B.
Its shares closed at $27.79 on 4 Nov 2026, up 22.2% over the past year.
From India you can buy BEAM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Beam Therapeutics Inc. (BEAM) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole BEAM share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade BEAM options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $27.79 was 7.9% above its 50-day average ($25.75) and 1.0% below its 200-day average ($28.07). It has closed below the 200-day for 4 sessions, since 30 Oct 2026. The 50-day average crossed below the 200-day on 14 Sep 2026, 37 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
14.1 days to cover short interest
26.2M shares were sold short at the 15 Oct 2026 settlement, 25.4% of the 103.3M shares outstanding; covering them would take 14.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +10.1% (SPY −1.6%, XLV +13.5%). 3 months: +2.7% (SPY −0.4%, XLV +15.5%). 1 year: +22.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BEAM, SPY and XLV · as of 4 Nov 2026
42% of the way up its 52-week range
Closed at $27.79 on 4 Nov 2026: 27.4% below the 52-week high of $38.26 (7 Jul 2026) and 37.4% above the low of $20.23 (20 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+10.1%

6 months−14.1%

1 year+22.2%

5 years−70.3%

Newswire

About

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Website

Notable moves

January 12, 2026
+22.29%
May 6, 2025
−19.32%
February 27, 2024
+25.89%

Newswire

About

Website

Notable moves

January 12, 2026
+22.29%
May 6, 2025
−19.32%
February 27, 2024
+25.89%

Beam Therapeutics Inc.

XNASHealth care

Last traded price · USD

$27.61

−0.65%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:04 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $27.79
Volume: 667
Day's high: —
Day's low: —

In brief

Beam Therapeutics Inc. is a health care company listed on Nasdaq, valued at about $2.85B.
Its shares closed at $27.79 on 4 Nov 2026, up 22.2% over the past year.
From India you can buy BEAM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Beam Therapeutics Inc. (BEAM) shares from India?

Do I need the price of a whole BEAM share to invest?

How much can I invest in US stocks in a year?

Can I trade BEAM options or futures?

Insights

Quotes run fifteen minutes behind.

Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $27.79 was 7.9% above its 50-day average ($25.75) and 1.0% below its 200-day average ($28.07). It has closed below the 200-day for 4 sessions, since 30 Oct 2026. The 50-day average crossed below the 200-day on 14 Sep 2026, 37 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
14.1 days to cover short interest
26.2M shares were sold short at the 15 Oct 2026 settlement, 25.4% of the 103.3M shares outstanding; covering them would take 14.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +10.1% (SPY −1.6%, XLV +13.5%). 3 months: +2.7% (SPY −0.4%, XLV +15.5%). 1 year: +22.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BEAM, SPY and XLV · as of 4 Nov 2026
42% of the way up its 52-week range
Closed at $27.79 on 4 Nov 2026: 27.4% below the 52-week high of $38.26 (7 Jul 2026) and 37.4% above the low of $20.23 (20 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+10.1%

6 months−14.1%

1 year+22.2%

5 years−70.3%

Newswire

About

Website

Notable moves

January 12, 2026
+22.29%
May 6, 2025
−19.32%
February 27, 2024
+25.89%

Newswire

About

Website

Notable moves

January 12, 2026
+22.29%
May 6, 2025
−19.32%
February 27, 2024
+25.89%

Beam Therapeutics Inc.

Beam Therapeutics Inc. in brief

Above its 50-day average, below its 200-day

14.1 days to cover short interest

Ahead of SPY, behind its sector fund XLV over 1 year

42% of the way up its 52-week range

Beam Therapeutics Inc.

Beam Therapeutics Inc. in brief

Above its 50-day average, below its 200-day

14.1 days to cover short interest

Ahead of SPY, behind its sector fund XLV over 1 year

42% of the way up its 52-week range